Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific demonstrated robust financial performance in Q4, with significant revenue growth across multiple segments, including a 35% year-over-year organic increase in Electrophysiology and a 16.1% growth in Cardiovascular revenues. The company reported a gross margin of 70.7%, surpassing consensus expectations and indicating improved product mix despite some tariff impacts. With consistent growth trends anticipated in the Electrophysiology market and an overall company growth expectation that exceeds peers, Boston Scientific is well-positioned for continued success in the competitive medical device sector.

Bears say

Boston Scientific experienced a decline in its operating margin, down 10 basis points year-over-year, attributed to increased research and development expenses despite a slight gross margin improvement. Organic growth rates have decelerated, falling from 15.3% in the third quarter of 2025 to 12.7% in the fourth quarter, primarily due to declining demand for the FARAPULSE system amid rising competition and slowing adoption rates for pulse field ablation technology. The company’s 2026 sales growth guidance of 10.5-11.5% is below prior consensus expectations, indicating potential challenges in meeting market forecasts and raising concerns about the company’s operational traction and overall financial performance.

Boston Scientific (BSX) has been analyzed by 19 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 19 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $108.32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $108.32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.